Alkermes (ALKS) Non-Current Assets (2011 - 2026)
Alkermes' (ALKS) quarterly Non-Current Assets came in at $2.9 billion in Q1 2026, up 380.89% year-on-year from $602.9 million in Q1 2025, and up 419.77% on a QoQ basis from $557.8 million in Q4 2025.
Alkermes (ALKS) Non-Current Assets (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Non-Current Assets data on file, last reported at $2.9 billion in Q1 2026.
- On a quarterly basis, Non-Current Assets rose 380.89% year-over-year to $2.9 billion in Q1 2026; TTM through Mar 2026 was $4.7 billion, a 86.59% increase from a year earlier, with the FY2025 full-year figure at $557.8 million, down 12.87% from the prior year.
- Non-Current Assets for Q1 2026 stood at $2.9 billion, up from $557.8 million in the prior quarter.
- Over the last five years, Non-Current Assets for ALKS reached as high as $2.9 billion in Q1 2026 and fell as low as $557.8 million in Q4 2025.
- Historically, Non-Current Assets has averaged $851.8 million across 5 years, with a median of $664.7 million in 2024.
- Across the five-year window, Non-Current Assets declined 27.42% in 2024 and jumped 380.89% in 2026, its largest moves.
- Year by year, Non-Current Assets stood at $833.7 million in 2022, then decreased by 21.95% to $650.7 million in 2023, then retreated by 1.61% to $640.2 million in 2024, then slipped by 12.87% to $557.8 million in 2025, then soared by 419.77% to $2.9 billion in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $2.9 billion in Q1 2026, $557.8 million in Q4 2025, and $587.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | 2.90 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.90 Bn |
| Dec 31, 2025 | 557.83 Mn |
| Sep 30, 2025 | 587.85 Mn |
| Jun 30, 2025 | 617.52 Mn |
| Mar 31, 2025 | 602.93 Mn |
| Dec 31, 2024 | 640.21 Mn |
| Sep 30, 2024 | 591.11 Mn |
| Jun 30, 2024 | 664.65 Mn |
| Mar 31, 2024 | 655.07 Mn |
| Dec 31, 2023 | 650.72 Mn |
| Sep 30, 2023 | 814.45 Mn |
| Jun 30, 2023 | 789.83 Mn |
| Mar 31, 2023 | 812.67 Mn |
| Dec 31, 2022 | 833.67 Mn |
| Sep 30, 2022 | 888.10 Mn |
| Jun 30, 2022 | 911.43 Mn |
| Mar 31, 2022 | 963.02 Mn |
| Dec 31, 2021 | 962.32 Mn |
| Sep 30, 2021 | 942.43 Mn |
| Jun 30, 2021 | 899.81 Mn |